Search results for "idebenone"

showing 6 items of 6 documents

Randomized, double-blind, placebo controlled, multicentre study of idebenone in patients suffering from multi-infarct dementia

1992

Abstract In this randomized double-blind, placebo controlled, multicentre study on 108 elderly patients with mild to moderate mental deterioration of vascular origin, idebenone — a benzoquinone derivative with a hydroxyalkyl side chain — proved to be therapeutically effective in the treatment of multi-infarct dementia. The oral administration of idebenone 45 mg/day b.i.d. for 120 days significantly improved the scores of the following test in comparison with placebo: Mini Mental State, Randt Memory Test, Gottfries Rating Scale, Token Test, Toulouse Pieron Test, indicating improvements in memory attention and cognitivity. The drug was well tolerated and effective in patients with multi-infar…

Agingmedicine.medical_specialtyHealth (social science)Vascular diseaseCerebral infarctionbusiness.industrymedicine.diseasePlaceboClinical trialOral administrationRating scaleAnesthesiamedicinePhysical therapyIdebenoneDementiaGeriatrics and GerontologybusinessGerontologymedicine.drugArchives of Gerontology and Geriatrics
researchProduct

Idebenone in senile dementia of Alzheimer type: A multicentre study

1992

Idebenone is a new cerebro-active drug, effective in dementia disorders, particularly indicated in primary degenerative dementias, i.e. Alzheimer's disease. This new molecule acts as an electron trapper and a free radical scavenger protecting mitochondrial membranes from lipid peroxidation. A multicentric, double-blind trial of idebenone (45 mg twice daily orally) vs. placebo was carried out on 102 elderly patients affected by Alzheimer-type dementia of mild or moderate severity. Idebenone was administered for 4 consecutive months, 45 mg twice daily. Clinical evaluations were performed at the time of enrollment (t0) and monthly thereafter (t30, t60, t90 and t120) and at follow-up (t150 ). T…

Agingmedicine.medical_specialtyHealth (social science)business.industrymedicine.diseasePlaceboFree radical scavengerSurgeryClinical trialDegenerative diseaseTolerabilityInternal medicineMedicineDementiaIdebenoneGeriatrics and GerontologyAlzheimer's diseasebusinessGerontologymedicine.drugArchives of Gerontology and Geriatrics
researchProduct

Deferiprone and idebenone rescue frataxin depletion phenotypes in a Drosophila model of Friedreich's ataxia

2013

Friedreich's ataxia (FRDA), the most common inherited ataxia, is a neurodegenerative disease caused by a reduction in the levels of the mitochondrial protein frataxin, the function of which remains a controversial matter. Several therapeutic approaches are being developed to increase frataxin expression and reduce the intramitochondrial iron aggregates and oxidative damage found in this disease. In this study, we tested separately the response of a Drosophila RNAi model of FRDA ( Llorens et al., 2007) to treatment with the iron chelator deferiprone (DFP) and the antioxidant idebenone (IDE), which are both in clinical trials. The FRDA flies have a shortened life span and impaired motor coord…

AtaxiaPyridonesUbiquinoneIronLife spanHyperoxiaBiologyPharmacologyMitochondrionmedicine.disease_causeAconitaseAntioxidantsAconitasechemistry.chemical_compoundIron-Binding ProteinsGeneticsmedicineAnimalsIdebenoneDeferiproneAconitate HydrataseHyperoxiaFrataxinClimbing capabilityGeneral MedicineMitochondriaDisease Models AnimalOxidative StressPhenotypechemistryFriedreich AtaxiaOxidative stressMutationFrataxinbiology.proteinDrosophilamedicine.symptomDeferiproneOxidative stressmedicine.drugGene
researchProduct

In Vitro Antioxidant Activity and In Vivo Topical Efficacy of Lipid Nanoparticles Co-Loading Idebenone and Tocopheryl Acetate

2019

Idebenone (IDE) is a strong antioxidant that has been proposed for the treatment of skin disorders, including skin ageing. Unfavorable physico-chemical properties make IDE a poor skin permeant where effectiveness could be improved by its loading into suitable delivery systems such as solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC). In this work, we designed novel IDE-loaded NLC containing tocopheryl acetate (VitE) as a liquid component to obtain a synergic effect between IDE and VitE. The resulting NLC showed small particle sizes (24&ndash

antioxidantAntioxidantDPPHmedicine.medical_treatment02 engineering and technologylipid nanoparticlesPharmacologytocopheryl acetatemedicine.disease_causelcsh:Technology030226 pharmacology & pharmacylcsh:Chemistry03 medical and health scienceschemistry.chemical_compoundphoto-protective effect0302 clinical medicineIn vivoSolid lipid nanoparticlemedicineIdebenoneGeneral Materials Scienceskin hydrationlcsh:QH301-705.5InstrumentationFluid Flow and Transfer ProcessesIdebenonelcsh:TChemistryProcess Chemistry and TechnologyGeneral EngineeringIn vitro toxicologytopical administrationlipid nanoparticle021001 nanoscience & nanotechnologylcsh:QC1-999kin hydrationComputer Science Applicationsantioxidantslcsh:Biology (General)lcsh:QD1-999Idebenone; tocopheryl acetate; lipid nanoparticles; antioxidants; topical administration; skin hydration; photo-protective effectlcsh:TA1-2040Tocopheryl acetatelcsh:Engineering (General). Civil engineering (General)0210 nano-technologylcsh:PhysicsOxidative stressmedicine.drugApplied Sciences
researchProduct

Preparation and physico-chemical study of inclusion complexes between idebenone and modified beta-cyclodextrins

1996

The inclusion properties of modifiedβ-cyclodextrins (trimethyl-β-cyclodextrin, dimethyl-β-cyclodextrin and hydroxypropyl-β-cyclodextrin) towards idebenone were compared with naturalβ-cyclodextrin. The inclusion complexes were prepared by different methods (coprecipitation, kneading, and freeze-drying) and characterized by differential scanning calorimetry, X-ray diffractometry, UV, CD and NMR spectroscopy. The results obtained by CD and NMR spectroscopy indicate a different orientation of idebenone in dimethyl-β-cyclodextrin with respect to other cyclodextrins. Stability constants of the complexes were determined in water at various temperatures and consequently thermodynamic parameters wer…

dissolution studyAqueous solutioncyclodextrinsChemistryCoprecipitationtechnology industry and agricultureGeneral ChemistryNuclear magnetic resonance spectroscopyCondensed Matter Physicscyclodextrins; idebenone; characterization of complexes; dissolution studycarbohydrates (lipids)idebenonecharacterization of complexesDifferential scanning calorimetrypolycyclic compoundsmedicineIdebenoneOrganic chemistrylipids (amino acids peptides and proteins)Free drugInclusion (mineral)DissolutionFood Sciencemedicine.drugNuclear chemistry
researchProduct

Cytoprotective Effect of Idebenone through Modulation of the Intrinsic Mitochondrial Pathway of Apoptosis in Human Retinal Pigment Epithelial Cells E…

2022

Idebenone is a ubiquinone short-chain synthetic analog with antioxidant properties, which is believed to restore mitochondrial ATP synthesis. As such, idebenone is investigated in numerous clinical trials for diseases of mitochondrial aetiology and it is authorized as a drug for the treatment of Leber’s hereditary optic neuropathy. Mitochondria of retinal pigment epithelium (RPE) are particularly vulnerable to oxidative damage associated with cellular senescence. Therefore, the aim of this study was to explore idebenone’s cytoprotective effect and its underlying mechanism. We used a human-RPE cell line (ARPE-19) exposed to idebenone pre-treatment for 24 h followed by conditions …

idebenone; ARPE-19 (human-RPE cell line); mitochondria; oxidative stress; nuclear factor erythroid 2-related factor (Nrf2); apoptosisoxidative streARPE-19 (human-RPE cell line)IdebenoneSettore BIO/14 - FARMACOLOGIAOxidative stressNuclear factor erythroid 2-related factor (Nrf2)Medicine (miscellaneous)ApoptosisGeneral Biochemistry Genetics and Molecular BiologyMitochondria
researchProduct